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CD105 and its ligand transforming growth factor b (TGFb) are modulators of angiogenesis, which drives tumour growth and
metastasis. Tumour microvessel density (MVD) has proven to be an important determinant of prognosis. In this study, we have
examined the prognostic value of MVD identified using Mabs to the pan-endothelial marker CD34 and to CD105 in 111 patients
with colorectal cancer. The Mab to CD105 preferentially reacts with angiogenic endothelial cells. Of the 111 patients studied, 38
were alive and 73 had died of the disease. The median MVD values counted using anti-CD34 and anti-CD105 were 5 (range 1.40–
9.00) and 3.10 (range 0.90–8.00), respectively. Kaplan–Meier survival analysis revealed that only MVD values obtained using CD105
Mab correlated with survival. Patients with a high MVD, above the median (3.10), showed the worst prognosis. A similar outcome
was observed when MVD was divided into quartiles. In order to ascertain if this strong expression of CD105 in the tumour
vasculature is reflected in patients’ plasma, circulating levels of CD105, TGFb1 and TGFb3 together with the receptor–ligand
complexes were quantified in patients with colorectal carcinoma and normal controls. Results showed that except for TGFb1, the
levels of all other molecules were significantly elevated compared with controls. The levels of CD105 were positively correlated with
Dukes’ stages. A lower TGFb1 level was noted in patients with carcinoma over the controls. Furthermore, TGFb3 and CD105/
TGFb3 complexes were markedly lowered in postoperative compared with preoperative plasma samples. Immunostaining revealed
that TGFb1 was expressed in cancer cells but TGFb3 in the stromal cells, whereas CD105 was exclusively expressed in vascular
endothelial cells of tumour blood vessels. In conclusion, this study demonstrates that MVD quantified using a Mab to CD105 is an
independent prognostic parameter for survival of patients with colorectal cancer, and that plasma levels of CD105, TGFb1, TGFb3
and CD105/TGFb complexes may be useful markers for assessing disease progression. These data have led us to propose that
quantification of these determinants may prove useful to monitor therapeutic efficacy in patients with colorectal cancer, especially
those who are being treated with antiangiogenic therapies.
British Journal of Cancer (2003) 88, 1424–1431. doi:10.1038/sj.bjc.6600874 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: angiogenesis; soluble CD105; microvessel density (MVD); TGFb
                                                             
Tumour growth and spread are absolutely dependent on their
ability to induce angiogenesis (Folkman, 1996). Following the
initial publication by Srivastava et al (1988) on human melanomas,
several subsequent studies have shown an inverse correlation
between high tumour microvessel density (MVD) and prognosis in
patients with many different types of cancer (de Jong et al, 2000;
Weidner, 1999, 2000). However, some authors have failed to find
such a correlation or paradoxically, particularly in colorectal
cancers, have observed that high MVD is associated with good
prognosis (Chung et al, 1996; Abdalla et al, 1999). We have
proposed that the reasons for these contradictory results may be
the use of different antibodies to endothelial cells (ECs), the
counting methods and the staining procedures including antigen
retrieval techniques (Wang et al, 1994). To obtain MVD data,
invariably, previous studies have used pan-endothelial antibodies,
for example, against von Willebrand factor, CD31 or CD34, which
although ideal for staining normal blood vessels, in our experience
are inefficient in recognising angiogenic EC. In contrast, CD105
(endoglin) is abundantly expressed in angiogenic EC, and
antibodies to it preferentially bind to EC of angiogenic tissues
(Krupinski et al, 1994; Wang et al, 1994; Burrows et al, 1995; Bodey
et al, 1998; Kumar et al, 1999; Brewer et al, 2000; Fonsatti et al,
2001; Akagi et al, 2002). Our hypothesis is that this selective
immunostaining by an antibody to CD105, that is, its ability to
distinguish tumour-associated EC and pre-existing vessels, will
reduce the incidence of false-positive staining of normal entrapped
vasculature in a cancerous mass (Thompson et al, 1987). In two
previous studies, we have reported the prognostic significance of
MVD identified by Mab to CD105 and of soluble CD105 in the
circulation of patients with breast cancer (Kumar et al, 1999; Li
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yet al, 2000b). Whether this is true for patients with colorectal
cancer had not been verified. Therefore, in the present study, we
evaluated the prognostic significance of MVD in tumour tissues
and soluble CD105 in the plasma collected from patients with
colorectal cancer. The MVD was determined using an Mab to
CD105, which is highly reactive with angiogenic blood vessels, and
a pan-EC antibody, CD34. Both TGFb1 and TGFb3 bind to CD105
and their functions are regulated by CD105 (Fonsatti et al, 2001).
TGFb1 and TGFb3 are also critical growth factors in tumorigen-
esis. Here, we have determined MVD using a pan-endothelial
marker and CD105 in colorectal cancers and have quantified
plasma levels of TGFbs (viz., 1 and 3) and their receptor, CD105
and receptor–ligand complexes. These data were correlated with
other clinical parameters. The results indicate that these molecules
may be of potential value as markers of angiogenesis in colorectal
cancer patients, who are being treated by antiangiogenic therapies.
MATERIALS AND METHODS
Patients
The source of paraffin-embedded sections from 111 patients, with
primary colorectal tumours with a minimal follow-up time of 5
years, was the same as previously reported (Table 1) (Abdalla et al,
1999). The histopathological parameters of each tumour were
ascertained by an experienced pathologist (NH) and assigned as
per Dukes’ staging system. The overall survival time was 5.60 years
(range 0.30–8.00), while the median survival time for those still
alive was 6.70 years (range 5.10–8.00 years). Since no plasma
samples were available from these patients, a new cohort
comprising 76 patients with colorectal cancer and 40 normal
controls were recruited. Clinical details of the colorectal cancer
patients are given in Table 2. Blood samples from patients with
colorectal cancer were obtained prior to any treatment. In
addition, blood samples were collected from 14 colorectal cancer
patients 2 weeks after surgery. Control samples from 40 subjects
were collected from healthy hospital staff or from individuals
hospitalised for colonoscopy. Exclusion criteria for all control
subjects were malignancy, acute or chronic liver and kidney
diseases, connective tissue disease, psoriasis, scleroderma, diabetes
and symptomatic vascular diseases. Plasma was harvested follow-
ing centrifugation at 2000g for 10min at 41C, aliquoted and stored
at  701C for analysis. Ethics Committee approval and informed
consent from all patients were obtained.
Immunochemical staining of CD105 and CD34
Procedures for the immunostaining of CD34 and CD105 were the
same as those published previously (Seon et al, 1997; Abdalla et al,
1999). Tissue sections were deparaffinised and treated with 3%
hydrogen peroxide to quench endogenous peroxidase activity,
microwave-treated in citrate buffer and then stained with antibody
to CD34 (1:100; QBEND-10; Serotec Ltd, Oxford, UK). Incubation
with biotinylated secondary antibody was followed with perox-
idase-conjugated streptavidin. The colour was developed with
diaminobenzidine tetrachloride, and finally sections were counter-
stained with Mayer’s haematoxylin. Negative controls consisted of
those sections where primary antibody was omitted. CD105 was
stained using mab, SN6h (Seon et al, 1997; Kumar et al, 1999). All
the slides were scanned to determine the most vascularised areas,
that is, ‘hot spots’. Usually the most vascularised areas were
located at the tumour periphery. The MVD was determined using a
Chalkley eyepiece graticule ( 100 magnification). The mean of
four Chalkley counts for each tumour was calculated and used in
the statistical analysis.
Immunohistochemical staining of TGFb1 and TGFb3
Staining for TGFb1 and TGFb3 has been described previously
(Ghellal et al, 2000). Briefly, 5mm thick cryostat sections were air
dried, fixed in cold acetone and then incubated with chicken anti-
TGFb1 (1:400 in PBS; R&D systems) or goat anti-TGFb3 (1:250 in
PBS; R&D systems) overnight at 4
oC. The sections were washed
three times with PBS and incubated with biotinylated anti-chicken
(1:250 in PBS) or anti-goat (1:125 in PBS) antibody in 1% goat
serum for 30min. The horseradish peroxidase (HRP)-conjugated
streptavidin (1:100 in PBS; Vector) was applied for 30min and
Table 1 Some clinical data and their prognostic significance in 111
colorectal cancer patients
Parameter No. of cases
Prognostic
significance
Median age 69.5 years (range 32–95) NA
Sex
Male 65 NS
Female 46 (P=0.5140)
Site of tumour
Colon 83 NS
Rectum 28 (P=0.5537)
Tumour stage
Dukes’ A 8 P=0.0002
Dukes’ B 58
Dukes’ C&D 45
Tumour grade
Well differentiated 13 NS
Moderately differentiated 61 (P=0.4450)
Poorly differentiated 9
Mucinous 24
Unknown 4
Lymph node
Involved 44
Not involved 67 P=0.0004
Current status
Dead 73 NA
Alive 38
NS=not significant; NA=not applicable; the P-values represent the prognostic
significance referred to the survival data in Figure 1 (panel E, F).
Table 2 Clinical data of the 76 colorectal carcinoma patients
Median age 67.4 year (range 31–93)
Sex
Male 39
Female 37
Site of tumour
Colon 38
Rectum 38
Dukes’ stage
A8
B2 2
C1 1
D3 5
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ystaining was revealed by 0.02% diaminobenzidine (DAB, Sigma)
and 0.3% hydrogen peroxidase in distilled water. The sections were
counterstained with Mayer’s haematoxylin.
The levels of TGFb1 and TGFb3 expression were semiquantified
by light microscopy without knowledge of the patients’ details. The
staining intensity was scored as negative ( ), moderately positive
(+) or strongly positive (++).
Quantification of CD105, TGFb1, TGFb3 and the
receptor–ligand complexes
The immunoassays for CD105, TGFb1, TGFb3 and the receptor–
ligand complexes have been described elsewhere (Li et al, 2000a).
Briefly, for the detection of TGFb1, 96-well white plates (Dynatech
Microfluor, VA, USA) were coated at 41C overnight with
100mlwell
 1 mouse Mab against TGFb1, TGFb2 and TGFb3
(Genzyme, MA, USA) at 1mgml
 1 in PBS. After blocking with
1% BSA in 0.1 M PBS and 0.1% Tween 20 (PBS–Tween) for 2h at
room temperature, plates were washed three times with PBS–
Tween. To release the mature TGFb1, plasma was treated using pH
2.0 buffer as described by Grainger et al (1995). The acid-activated
samples were then transferred to the coated plate. A standard
curve was generated using purified recombinant human TGFb1
(R&D Systems, Abingdon, UK). The plate was left at 4
oC overnight
in a humidified chamber. Subsequently, the wells were incubated
with 100ml polyclonal chicken anti-TGFb1 antibody (R&D
Systems, Abingdon, UK), diluted 1:1000 (1mgml
 1) in PBS–
Tween, for 3h at 41C. Three washes with PBS–Tween were given
between each procedure. After washing, the plates were incubated
on a shaker with 100mlwell
 1 of rabbit anti-chicken IgG
conjugated to HRP (Jackson ImmunoResearch Laboratories Inc.
PA, USA), at 1:2000 dilution (0.2mgml
 1) in 1% BSA and PBS–
Tween, for 30min at room temperature. Finally, the plates were
rinsed three times, 100ml Amerlite signal reagent (Amersham, UK)
was added to each well, and the plate was read immediately in an
Amerlite plate reader (Kodak Clinical Diagnostics, Aylesburg, UK).
All the samples were run in duplicate and the measured values of
light emission at 420nm were converted into absolute TGFb1
concentrations by reference to the standard curve.
TGFb3 was quantified using the same procedure as for TGFb1,
with the exception that the chicken anti-TGFb1 was substituted
with goat anti-TGFb3 (R & D systems, Abingdon, UK) and the
untreated plasma was used for TGFb3 quantification.
Soluble CD105 was measured using an indirect sandwich ELISA
(Li et al, 2000b), wherein purified Mab E9, which specifically reacts
with CD105, and biotinylated Mab E9, in conjunction with
streptavidin peroxidase, were used as capture and detection
reagent, respectively. White microtitre plates were coated with
Mab E9 (100mlwell
 1) diluted 1:1000 (1mgml
 1) in 0.1 M PBS and
incubated overnight at 4
oC. The coated plates were blocked using
1% BSA and PBS–Tween for 2h at room temperature. Test
samples diluted 1:2 in PBS–Tween were added to the plates in
duplicate. One plasma sample with a high level of CD105
(approximately 100ngml
 1) was titrated to make a standard
curve in each plate. After incubation overnight at 4
oC,
100mlwell
 1, biotinylated Mab E9 (1:2000 dilution; 0.2mgml
 1)
was added to the plates and incubated at 4
oC in a humidified box
for 3h, followed by addition of 100mlwell
 1 of streptavidin
conjugated to HRP at 1:2000 dilution in PBS–Tween and 1% BSA,
which was incubated, with shaking, for 30min at room tempera-
ture. Three washes with PBS–Tween were carried out between
each of the procedures. Finally, 100mlwell
 1, Amerlite signal
reagent (Amersham) was applied to each well and the light
emission at 420nm was immediately measured in an Amerlite
plate reader.
The procedure for quantifying soluble CD105/TGFb1 complex
was the same as described in the assay for TGFb1, with the
exception that the coating anti-TGFb antibody was substituted by
Mab E9 at 1mgml
 1 in order to capture the complex from the
serum. A serum sample with a high level of CD105/TGFb1 complex
(100 arbitrary unitsml
 1) was serially diluted from 1:2 to 1:512 to
generate a standard curve on each plate. The assay showed no
crossreaction with CD105/TGFb3 complex and exhibited a wide
range of detection from 0.05 to 100Uml
 1. In the assay for CD105/
TGFb3 complex, Mab E9 was used as the coating antibody to
capture the complex from the plasma. The other procedures were
the same as described in the assay for TGFb3. The standard curve
was generated using a plasma sample containing 50Uml
 1 of the
complex on each plate.
The sensitivity of the assays for CD105, TGFb1, TGFb3, CD105/
TGFb1 and CD105/TGFb3 complexes was 0.10ngml
 1,1 0p gm l
 1,
30 pgml
 1, 0.05Uml
 1 and 0.03Uml
 1, respectively.
Statistical analysis
Statistical analysis was performed using Mann–Whitney
and Kruskal–Wallis tests of central location, Spearman’s
correlation and survival analysis using log regression and
Kaplan–Meier graphs with log-rank tests. CD34 and CD105 were
treated as continuous ratio variables, although they were divided
into quartiles for the purpose of survival analysis with
Kaplan–Meier graphs. Their association with other parameters
such as age or tumour size was measured with Spearman’s
correlation coefficient. Medians of CD34 and CD105
were tabulated for groups of each categorical variable, such as
stage. Differences between the medians were tested using the
Mann–Whitney or Kruskal–Wallis tests. Kaplan–Meier graphs
and log-rank tests were used to determine the prognostic value of
the MVD data for overall survival. Multivariate models (Cox
proportional hazards) were applied to determine their prognostic
value relative to standard factors such as stage. Greenwood’s
confidence intervals identified how survival differed between
quartiles.
For plasma levels of CD105, TGFb1, TGFb3 and the complexes,
results were expressed as mean7s.e.m. and median (range).
Differences between groups (viz, controls vs carcinoma; preopera-
tive vs postoperative patients) were determined using nonpara-
metric Mann–Whitney U-test. Correlation analysis was performed
using Kendall’s tau_b test. A P-value of p0.05 was considered
significant.
RESULTS
Microvessel density
Of the 111 patients, 73 died – Dukes’ stage C and D combined
patients had the shortest survival time and positive lymph nodes
indicated poor survival (Figure 1 E, F and Table 1). Survival was
not significantly affected by grade, site, patient’s age or gender. As
shown in Figure 2, staining for both CD34 and CD105 was
heterogeneous. The most highly vascularised areas were invariably
observed at the tumour periphery and in the immediate vicinity of
normal tissues. The median MVD values for CD34 and CD105 were
5 (range 1.40–9.00) and 3.10 (range 0.90–8.00), respectively. Of
the 111 tumours stained with CD34, 56 had microvessel counts
below the median, and 55 above the median. The corresponding
numbers for CD105 above and below the median were 60 and 51,
respectively. The MVD values were also divided into quartiles
(CD34: o3.80, o5.00, o6.00 and 6.00+, and CD105: o2.00,
o3.00, o5.00 and 5.00+). The survival for patients based on these
data is shown in Figure 1 A–D.
Kaplan–Meier survival analysis indicated that MVD obtained
using CD34 showed no significant correlation with survival.
The same result was noted when MVD was divided by either
median value (Figure 1A) or by quartiles (Figure 1B), demonstrating
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ythat microvessel counts using CD34 were not correlated
with prognosis. In sharp contrast, high MVD counts determined
using CD105 were strongly associated with a poor prognosis
(Figure 1 C, D). The 5-year survival rate of patients with
MVD greater than the median (3.10) was less than 20%, while it
was 60% in those with MVD below 3.1 (P¼0.0001). An inverse
correlation between MVD and survival time was also observed
when MVD counts were divided into quartiles. Approximately 65%
of the patients survived more than 5 years in the group with MVD
less than 2. A high MVD recognised by CD105 indicated poor
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Figure 1 Kaplan–Meier survival graphs showing percent survival of patients with colorectal cancer. Microvascular density data obtained using Mabs to
CD34 and CD105 were divided into above and below median (A, C) and into quartiles (B, D). Microvessel density values obtained using CD105 showed
that high microvessel counts indicated poor prognosis, but there was no significant correlation with MVD values given by CD34. In addition, patients with
Dukes’ stage C and D (combined) (E) or positive lymph nodes (F) survived the shortest time. The P-values were obtained by log-rank tests.
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shortest time (Figure 1D). MVD values obtained using
CD105 showed no statistically significant correlation with
values obtained with CD34. There was no significant correlation
between Dukes’ stage or lymph node involvement with MVD
values given by either CD34 or CD105 (data not shown). CD105
and a panel of other prognostic values were tested for survival
using Cox proportional hazard models. Briefly, it emerged that
only CD105, lymph node involvement and Dukes’ stage were
significant as independent prognostic variables. Combined statis-
tics (multivariate analysis) showed that CD105 was an independent
prognostic factor for survival. In multivariate models, the
prognostic significance of a variable depends on the prognostic
significance of MVD values using Mab to CD105 and vice versa.
Thus, CD105 remained significant whatever variable is added to
the model.
Expression of TGFb1 and TGFb3 in tumour tissues
Immunohistochemical staining of TGFb1 and TGFb3 in tumour
tissues revealed their distinctive expression pattern. TGFb1 was
expressed exclusively in tumour cells, while TGFb3 was expressed
mainly in tumour stromal tissues (Figure 3). The expression
intensity of TGFb1 and TGFb3 was analysed for patients’ survival
using Cox’s proportional hazard model. Neither TGFb1 nor TGFb3
was significantly correlated with overall survival (P¼0.2740 and
P¼0.6990, respectively). Further analysis revealed no significant
correlation with other clinical parameters.
CD105 CD34
Figure 2 Expression of CD105 and CD34 in tumour vasculature. Serial sections of colon carcinoma were stained with Mabs to CD105 or CD34.
Although the majority of blood vessels were stained by both Mabs, a proportion of the vessels reacted only with CD105 but not with CD34 ( ),
demonstrating the distinctive expression of CD105 and CD34 in tumour vasculature ( 250).
TGFß3 TGFß1
Figure 3 Expression of TGFb1 and TGFb3 in tumour tissues. Colon carcinoma tissue sections were stained with antibody to TGFb1 or to TGFb3. TGFb1
was localised in the cytoplasm of the tumour cells. In contrast, the expression of TGFb3 was mainly in the stromal cells ( 250).
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receptor–ligand complexes
The results for the molecules quantified in the plasma are
summarised in Table 3. CD105 was detected in 95% (72 out of
76) of the colorectal cancer patients in contrast to 80% (32 out of
40) in the normal controls. Significantly elevated CD105 levels
were seen in cancer patients compared with controls (P¼0.0001).
Furthermore, a positive correlation was observed between CD105
levels and the Dukes’ stages, for example, patients with advanced
cancer possessed higher CD105 levels than those with early-stage
disease (r¼0.20, P¼0.0470). The lack of a significant difference
between pre- and postoperative samples may be indicative of
postoperative angiogenesis during the process of wound healing,
which is likely to overshadow a lowered CD105 level following
removal of the tumour.
With regard to TGFb1, lower levels were seen in patients with
cancer compared with controls. It neither differed in pre- and
postoperative samples nor was correlated with a particular Dukes’
stage. Correlation analysis revealed an inverse correlation between
TGFb1 levels and the number of positive lymph nodes (r¼ 0.48,
P¼0.0110), that is, those patients with elevated TGFb1 levels
possess fewer positive lymph nodes than those with lower TGFb1
levels. The levels of CD105/TGFb1 complexes were significantly
increased in patients with cancer, and were inversely correlated
with node involvement (r¼ 0.26, P¼0.0330).
TGFb3 was detected in 79% (60 out of 76) of patients with
colorectal cancer. The levels of TGFb3 in both groups of patients
were significantly elevated compared with controls. Comparison of
TGFb3 levels in pre- and postoperative samples showed a
significantly lower level in the latter (P¼0.0080). However, TGFb3
levels were increased in the two postoperative patients, an
indication of possible relapse or tumour metastasis (Li et al,
1998). The same trend was noticed with CD105/TGFb3, that is, a
lower level in controls compared with cancer patients. In
comparison between pre- and postoperative samples, the latter
possessed less CD105/TGFb3 except for the two patients men-
tioned above whose CD105/TGFb3 levels were markedly elevated
after operation (Table 3). No significant correlation was found
between either TGFb3 or CD105/TGFb3 complexes and a Dukes’
stage.
DISCUSSION
In this study, we have evaluated the prognostic significance of
intratumoral MVD identified using antibodies to CD105 or CD34.
These data demonstrate that MVD quantified by only Mab to
CD105 correlated with prognosis. Quantification of circulating
CD105, its ligands TGFb1 and TGFb3 and the ligand–receptor
complexes revealed elevated levels of CD105, TGFb3, CD105/TGFb3
and CD105/TGFb1 complexes but not TGFb1 in patients with
colorectal cancer. Furthermore, the levels of CD105 were correlated
with Dukes’ stages. This study suggests that MVD examined using
Mab to CD105 and the circulating levels of CD105 are of prognostic
significance in patients with colorectal carcinoma.
That the MVD using CD34 was not correlated with prognosis
raises important issues. It is not the first time that determination
of MVD using a pan-endothelial marker has failed to be correlated
with prognosis. For instance, in thyroid and laryngeal squamous
cell carcinomas, MVD was not associated with disease-free or
overall survival (Akslen and Livolsi, 2000; Pignataro et al, 2001).
Furthermore, MVD was even positively correlated with better
prognosis in renal cell carcinoma (Sabo et al, 2001). In both these
studies, a Mab to CD34 was used to determine the MVD. There is
an obvious difference between the reactivity of the two Mabs
utilised in the present study. CD34 is an excellent marker for the
normal vasculature, whereas CD105 antibody is more discrimina-
tory in its staining of microvessels. By immunostaining of a variety
of tissues, we and others have observed that whereas Mab to
CD105 has a high affinity for angiogenic blood vessels (e.g. in
tumours, stroke and psoriatic tissues), it often fails to react with
the normal microvessels decorated by pan-endothelial markers, for
example, CD31, vWF, CD34, PAL-E (Burrows et al, 1995; Kumar
et al, 1996; Bodey et al, 1998; Miller et al, 1999; Brewer et al, 2000;
Fonsatti et al, 2001 and our unpublished data). These observations
demonstrate that CD105 and the pan-endothelial markers are
differentially expressed in angiogenic and normal EC, and that the
former is more suitable for identifying tumour angiogenesis. It is
possible that colorectal cancers acquire their vasculature both by
incorporation of normal vessels of the host (which are recognised
by CD34 and other pan-endothelial markers) and induction of new
blood vessels, that is, angiogenesis (recognised by CD105). The two
sets of vasculature are thought to be functional in supporting
Table 3 Plasma levels of CD105, TGFb1, TGFb3, and CD105/TGFb complexes for patients with colorectal carcinoma and controls
Groups CD105 (ngml
 1) TGFb1 (pgml
 1)T G F b3 (ngml
 1) CD105/TGFb1( Um l
 1) CD105/TGFb3( Um l
 1)
Controls 0.9270.17 181.80725.05 0.3470.06 0.6070.16 0.0470.02
N=40 0.70 118.60 0.23 0.00 0.00
(0–3.45) (67.80–278.00) (0.05–1.52) (0–2.70) (0–0.36)
Carcinoma 3.4671.30 34.4474.69 1.5470.44 1.7970.24 1.3070.33
N=76 1.89 30.00 0.400 1.200 0.41
(0–100.00) (0–207.00) (0–21.80) (0–12.50) (0–16.45)
(P=0.0001) * (P=0.0001) * (P=0.0460) * (P=0.0010) * (P=0.0001) *
Preoperative 2.0770.28 43.07714.56 0.5970.08 1.3570.28 0.4870.08
N=14 2.01 29.00 0.44 1.15 0.46
(0.59–4.55) (0–205.00) (0.19–1.10) (0–4.50) (0.08–1.16)
Postoperative 2.9770.39 27.8777.90 1.2070.72 3.7671.51 3.4073.02
N=14 3.00 23.13 0 0.80 0
(0.70–5.30) (0–114.00) (0–8.23) (0–16.90) (0–42.54)
(P=0.1130) ** (P=0.5300) ** (P=0.0080) ** (P=0.8890) ** (P=0.0080) **
Data are expressed as mean7s.e.m. and median (range). The P-values obtained by nonparametric Mann–Whitney U-test for controls vs carcinoma and preoperative vs
postoperative groups are indicated by * and **, respectively.
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CD105, but not by Mab to CD34, correlated with prognosis? It is
possible that high microvessel counts identified by CD105
represent a high profile of angiogenesis in tumours that are more
progressive and likely to metastasise. In contrast, MVD identified
by CD34 (and other pan-endothelial markers) may not be able to
accurately characterise angiogenesis of certain types of tumour,
leading to a lack of association of MVD with tumour progression.
This speculation is supported by a recent study by Akagi et al
(2002), who have reported that a significant increase of MVD
determined by Mab to CD105 but not Mab to CD34 was observed
from low-grade to high-grade dysplasia of colorectal mucosa, and
from high-grade dysplasia to colorectal carcinoma. In conclusion,
the ability to quantitatively discriminate between angiogenesis and
pre-existing vessels in tumours seems to be an important
determinant in the assessment of tumour angiogenesis. Hence,
MVD identified using Mab to CD105 proved superior over pan-
endothelial markers such as CD34 in assessing the prognosis of
patients with colorectal cancer.
With regard to the circulating levels of CD105, TGFb1, TGFb3
and the receptor–ligand complexes, the results indicate that except
for TGFb1, the levels of the other molecules were markedly
elevated in cancer patients compared with controls. Correlation
analysis has revealed that CD105 is the only one that was positively
correlated with a Dukes’ stage. Furthermore, decreased levels of
TGFb3 and CD105/TGFb3 complexes were noted in postoperative
compared with preoperative samples. These observations strongly
suggest that CD105, TGFb3 and CD105/TGFb3 complexes in the
circulation may be of prognostic value in patients with colorectal
cancer.
Raised levels of CD105 and TGFb3 were found in plasma
samples from colorectal cancer patients, which are in agreement
with previous observations (Li et al, 1998, 2000b). Published data
indicate that CD105 is strongly expressed in blood vessels in
cancer tissues but weakly in normal tissues. Therefore, it is
reasonable to assume that increased CD105 in the circulation of
patients with cancer resulted from angiogenesis both within and in
the immediate vicinity of the tumour mass. That CD105 levels were
positively correlated with a Dukes’ stage, was entirely consistent
with the observation in patients with breast cancer, wherein
significantly elevated CD105 levels were found in patients who
subsequently relapsed or developed metastatic disease (Li et al,
2000b). A recent publication also supports the conclusion that
patients with lymph node metastasis possess markedly elevated
CD105 levels in the circulation (Takahashi et al, 2001). These data
prompt us to propose that CD105 is an angiogenic marker that can
be used for monitoring tumour metastasis and relapse.
Tumour cells produce TGFb1 and TGFb3 as shown in the
current and previous studies (Ghellal et al, 2000). Their distinct
tissue localisation in colorectal tumours implies that the two
isoforms may orchestrate different biological functions in tumour
development. In line with this speculation, TGFb3 but not TGFb1,
has been found to be positively associated with lymph node
metastasis in breast cancer patients and inversely correlated with
the survival of patients with osteosarcoma (Kloen et al, 1997; Li
et al, 1998), suggesting that modulating role of TGFb3 in tumour
progression may differ in various tumour types. The underlying
mechanism is not fully understood, but its proangiogenic action
may contribute to the stimulating effects in tumour progression
(Gold et al, 2000; Li et al, 2001). In this study TGFb3 levels were
increased, although not significantly, as the disease progressed.
The lack of a statistical significance is likely to be the result of
having a relatively small number of patients in each group and a
large variation in the TGFb3 levels. With respect to TGFb1,
although published data show inconsistency, it is generally
accepted that TGFb1 acts as a tumour suppressor, particularly at
an early stage of the disease (Rich et al, 2001). A lower TGFb1 level
was observed in patients with colorectal cancer compared with
controls, which may have been resulted from the elevated CD105/
TGFb1 complex levels in the same patients. The inverse correlation
between TGFb1 levels and the number of positive lymph nodes
indicates that TGFb1 may play a role in suppressing node
metastasis, which is consistent with a previous observation
(Gohongi et al, 1999).
To summarise, we have investigated the prognostic significance
of the angiogenic marker CD105 and its ligands TGFb1 and TGFb3
in patients with colorectal cancer by immunohistochemistry and
ELISAs. The conclusions are that a high MVD, identified using
Mab to CD105, predicts a poor prognosis, and that circulating
CD105, levels are positively correlated with Dukes’ stage. There-
fore, CD105, as a novel marker of tumour angiogenic activity, may
prove to be valuable in assessing the prognosis of patients with
colorectal cancer, especially in those patients who are receiving
antiangiogenic therapies. Indeed our preliminary unpublished data
show that the circulating levels of CD105 and CD105/TGFb
complexes dramatically decreased in individuals who had been
treated by a variety of antiangiogenic agents. These findings are
part of an ongoing clinical trial and thus their precise clinical
usefulness has not been evaluated.
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